HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 10/15/2012 -- Tesla Motors, Inc (NasdaqNM:TSLA) are trading at $27.64 and is -4.89% from its 50-day Moving Average price of $29.0617 and -10.13% from its 200-day Moving Average price of $30.7542. The average trading volume is 1411650 shares and its market capitalization is $2.914B. Tesla Motors Inc(NASDAQ:TSLA) shares declined 0.99% to $28.04 in the morning hour. The company received a $10 million grant from California to buy assembly equipment and add 500 workers to build a rechargeable sport-utility vehicle in the state. The California Energy Commission awarded the funds to reimburse Tesla for machinery purchased to equip its Fremont, California, factory to produce the battery-powered Model X crossover. Additionally, TSLA’s stock had its “buy” rating reaffirmed by research analysts at Jefferies Group in a report released this week.
How Should Investors Trade TSLA Now? FIND OUT HERE
Lexicon Pharmaceu (NasdaqNM:LXRX) reported EPS of -0.281. For the Current Fiscal year, the company is expected to report EPS of -0.22. For the Next Quarter and Next Year, the company is expected to report EPS of -0.06 and -0.19 respectively. At Current Market Price, LXRX is in distance of +10.61% from its 50-day Moving Average price of $2.432 and +28.22% from its 200-day Moving Average price of $2.0979. Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX) stock climbed 10.46% to $2.64 in the pre-market hour after the company announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate. Results from the trial will be presented at the North American Neuroendocrine Tumor Society on October 13, 2012 in San Diego, California.The primary efficacy endpoint of the trial was the reduction of bowel movements from baseline in patients with metastatic carcinoid syndrome who were refractory to or could not tolerate somatostatin analog therapy. Patients experienced a 46.4% median reduction from baseline at week 12, with the number of daily bowel movements steadily decreasing over time.Lexicon Pharmaceuticals Inc. (LXRX, $2.61, +$0.22, +9.20%) said top-line results from a midstage study for telotristat etiprate, its investigational new drug to treat carcinoid syndrome, were positive. The drug currently has fast track status and orphan drug designation for the U.S. Food and Drug Administration, and orphan drug designation from the European Medicines Agency.
How Should Investors Trade LXRX Now? CLICK HERE
Hunt Transpo (NasdaqNM:JBHT) is +3.58 - +6.53% from the previous close of $54.79. It traded between $57.52 - 59.47 with total traded volume of 3991028 shares. Keep a close eye on JBHT, as the stock has been showing unusual moves over the past weeks. At Current market price, JBHT has recovered +43.80% from its 52-week Low of 40.59 and has Pulled back -4.59% from its 52-week high of 61.18. J.B. Hunt Transport Services, Inc (NASDAQ:JBHT) soared 6.53% on Friday after the transportation company reported 14% increase in net profits in the fiscal third quarter even as sales rose compared to the year earlier quarter thanks to volume growth across Intermodal (JBI) and Integrated Capacity Solutions (ICS) divisions which helped in offsetting higher expenses in the Dedicated Services (DCS) and Truck (JBT) divisions. The company reported earnings of 65 cents a share, missing analysts’ consensual estimate of 66 cents a share but 8 cents a share higher than year earlier quarter. Total revenue jumped by 10.6% to $1.30 billion. Analysts’ polled by Thomson Reuters had forecasted revenue of $1.28 billion. In the fiscal third quarter, J.B. Hunt’s operating income climbed 12.1% YOY basis to $133.1 million. The operating margin came at 10.3%, up 20 basis points (bps) YOY basis.
Should Investors Exit From JBHT : CLICK HERE
Shares of Patrick Industrie (NGM:PATK) are trading at $18.09 and is +21.44% from its 50-day Moving Average price of $14.8966 and +40.18% from its 200-day Moving Average price of $12.9047. The average trading volume is 117906 shares and its market capitalization is $190.3M. Patrick Industries, Inc.(NASDAQ:PATK) stock increased 11.46% to $17.50. The company, last month, said that it has acquired the business and certain assets of Creative Wood Designs, Inc., a manufacturer of hardwood furniture. Creative is based in Ligonier, Indiana and has 2012 annual revenues guidance to be about $18 million. The purchase price for the assets was about $5.7 million, including a contingent payment based on future performance, and was funded under the company’s revolving credit facility.
How Should Investors Trade PATK Now? FIND OUT HERE
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)